IlluminOss Medical receives two patents related to its internal bone fixation system

ILLUMINOSS has been issued two patents related to its internal bone fixation system, bringing to 25 the total of U.S. patents.
ILLUMINOSS has been issued two patents related to its internal bone fixation system, bringing to 25 the total of U.S. patents.

(Updated 3:48 p.m.)

EAST PROVIDENCE – IlluminOss Medical has been issued two patents related to its internal bone fixing system, the company announced Tuesday.

IluminOss, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, now owns 25 issued U.S. patents. Its complete intellectual property portfolio includes more than 55 issued patents in 17 countries around the world.

The two U.S. patents that were issued on Dec. 9 cover internal bone fixation devices and kits for repairing a weakened or fractured bone, as well as internal bone fixation devices and systems for internal fixation of a fractured bone.

- Advertisement -

The proprietary IlluminOss System incorporates the use of a thin-walled balloon infused with a liquid monomer and inserted into the intramedullary canal of the bone, which then conforms to the shape of the patient’s specific bone. The device forms as an implant once the surgeon activates the visible light delivered within the PET balloon. Once cured, the implant provides longitudinal strength and rotational stability over the length of the implant, according to information provided by the company.

In other news, the company recently received conditional approval from the U.S. Food and Drug Administration to conduct a clinical trial in the United States for the treatment of impending and pathologic fractures in the humerus due to metastatic carcinoma.

“2014 has been a pivotal year for IlluminOss, as we have continued to see successful results from the use of our orthopedic implant system in international markets and now the enrollment process is underway for our first U.S. clinical trial,” Robert Rabiner, president and CEO of IlluminOss Medical, said in a statement. “We are confident that our unique approach to fracture repair will be a true game changer in how orthopedic surgery will be performed around the world, and we have made significant strides in the last 12 months towards furthering our place in the market and safeguarding IlluminOss’ intellectual property.”

IlluminOss’ minimally invasive procedure enables surgeons to create a patient-conforming implant, which can allow the patient to return to daily activities more quickly without being hindered by a hard cast. Benefits of the product include smaller incisions, shorter procedure times and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates.

Since its founding in 2007, IlluminOss has raised $50 million in funding from national and international sources.

Rabiner took over the CEO position in September after the departure of Dirk Kuyper, who was hired in April 2013. Kuyper took over for Scott Rader, whose position with the company ended in late October 2012. At the time, the company said it wanted a CEO with more sales and marketing experience.

Rabiner said 2014 has been a critical year for the company, noting strides made in international markets.

“As we continue to grow and evolve as a company, it has been important to build the right strategic team that shares our vision and has the right skillset to further our goal of making IlluminOss’ approach to fracture repair a game changer in how orthopedic surgery will be performed worldwide. This has required some transitions amongst our staff, as is to be expected,” Rabiner said.

No posts to display